Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)
₹30.18 +0.94% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Biofil Chemicals' revenue was ₹12.4 Cr (+92.1% year on year, +63.1% on the previous quarter), and net profit ₹0.1 Cr (-95.5% year on year); the operating margin was 1.1%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹12.4 | +92.1% | +63.1% |
| Operating profit | ₹0.1 | — | -67.3% |
| Net profit | ₹0.1 | -95.5% | -48.0% |
| EPS (₹) | 0.07 | -95.3% | -46.2% |
| Operating margin | 1.1% | — | — |
BIOFILCHEM delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 79.34% of the BIOFILCHEM shares traded on NSE were taken to delivery, against the stock's own 20-session average of 65.31%. That is higher than usual for this stock. Turnover was only ₹1 lakh, so a handful of trades can move this figure. Volume was under a tenth of its average.
Delivery in the last 5 sessions: 76.0% · 71.8% · 66.6% · 82.8% · 79.3%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Biofil Chemicals and Pharmaceuticals Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate from Registrar and Share Transfer Agent, Ankit Consultancy Private Limited, confirms that securities received for dematerialization were processed within 15 days. Security certificates were verified, cancelled, and the depository names substituted in the register of members. This is a regular administrative disclosure with no financial impact.
- Compliance certificate filed under Regulation 74(5) for the quarter ended September 30, 2026
- Confirmation provided by Registrar and Share Transfer Agent Ankit Consultancy Private Limited
- Dematerialization requests confirmed, mutilated, and cancelled within the mandated 15 days
Biofil Chemicals & Pharmaceuticals Limited announced that its shareholders approved the continuation of Mr. Ashok Kumar Ramawat as Non-Executive Independent Director at its 41st Annual General Meeting held on September 23, 2026. The approval was required under SEBI Regulation 17(1A) as Mr. Ramawat will attain the age of 75 years on September 27, 2027. Mr. Ramawat possesses 46 years of post-qualification experience in the pharmaceuticals industry. This is a routine corporate governance compliance measure with no direct financial impact on the company.
- Shareholder approval obtained at the 41st AGM held on September 23, 2026
- Approves continuation of directorship upon attaining 75 years of age on September 27, 2027
- Director Mr. Ashok Kumar Ramawat has 46 years of post-qualification pharmaceutical industry experience
- AGM proceedings concluded in 14 minutes, from 03:03 P.M. to 03:17 P.M.
Biofil Chemicals and Pharmaceuticals announced that all resolutions proposed at its 41st Annual General Meeting held on September 23, 2026, were passed with requisite majority. Approved items include the adoption of FY26 financial statements, reappointment of director Mr. Smitesh Shah, and continuation of independent directorship for Mr. Ashok Kumar Ramawat. Additionally, an ordinary resolution approving material related-party transactions with Cyano Pharma Private Limited was approved by non-promoter public shareholders (99.96% votes in favour of votes polled).
- All resolutions approved at the 41st AGM held on September 23, 2026
- Material Related Party Transaction with Cyano Pharma approved with 99.962% votes in favour
- Promoter voting on the related party resolution was 0 votes polled due to interested party rules
- Reappointment of director Mr. Smitesh Shah passed with 99.9998% voting in favour
Biofil Chemicals & Pharmaceuticals Limited has notified the exchanges regarding its 41st Annual General Meeting (AGM), scheduled for September 23, 2026, via Video Conferencing. The cut-off date for determining shareholder voting entitlement is September 16, 2026. Remote e-voting will be open from September 20, 2026 (9:00 AM) to September 22, 2026 (5:00 PM). A total of four resolutions will be placed before members, with scrutinizer results to be announced within two working days of the AGM.
- 41st Annual General Meeting scheduled for September 23, 2026, at 3:00 PM IST via VC/OAVM
- Cut-off date for remote e-voting eligibility set for September 16, 2026
- E-voting window open from September 20, 2026 (9:00 AM) to September 22, 2026 (5:00 PM)
- Total of 4 resolutions placed for shareholder approval
- Scrutinizer voting results to be declared within 2 working days post-AGM
Biofil Chemicals & Pharmaceuticals Limited has submitted a draft letter to be dispatched to shareholders whose email addresses are not registered with the company, depository participants, or RTA. The letter details access instructions for the FY 2025-26 Annual Report and notice for the upcoming 41st Annual General Meeting (AGM). The AGM is scheduled to be held virtually on September 23, 2026, at 3:00 PM IST.
- 41st Annual General Meeting scheduled for September 23, 2026, at 3:00 PM via Video Conferencing (VC/OAVM)
- Pertains to the Annual Report and financial statements for the financial year ended March 31, 2026
- Issued under Regulation 36(1)(b) of SEBI (LODR) Regulations, 2015 for shareholders with unregistered email IDs
- Shareholders can request physical copies or update details with RTA Ankit Consultancy Private Limited
Biofil Chemicals & Pharmaceuticals Limited has issued notice for its 41st Annual General Meeting (AGM) scheduled for September 23, 2026, via Video Conferencing. Key agenda items include adopting the FY26 audited financial statements, re-appointing Non-Executive Director Mr. Smitesh Shah, and approving the continuation of Independent Director Mr. Ashok Kumar Ramawat beyond age 75. Most notably, the company is seeking shareholder approval for material Related Party Transactions with Cyano Pharma Private Limited for an aggregate value up to ₹20 Crores for FY 2026-27.
- 41st AGM scheduled to be held on September 23, 2026, at 3:00 PM IST via Video Conferencing.
- Proposed approval for Material Related Party Transactions with Cyano Pharma Private Limited up to ₹20 Crores for FY 2026-27.
- Proposed ₹20 Crores RPT limit equals ~58.8% of the company's TTM revenue of ₹34 Crores.
- Special resolution tabled for continuation of Independent Director Mr. Ashok Kumar Ramawat upon attaining 75 years of age on September 27, 2027.
- Re-appointment of Mr. Smitesh Shah (holding 1,86,662 shares or 1.15%) as Non-Executive Non-Independent Director.
Biofil Chemicals & Pharmaceuticals Limited has approved the continuation of Mr. Ashok Kumar Ramawat as a Non-Executive Independent Director, despite him reaching the age of 75. This decision follows the recommendation of the Nomination and Remuneration Committee and requires a Special Resolution from shareholders at the upcoming 41st Annual General Meeting. Mr. Ramawat, originally appointed in August 2020, brings 46 years of pharmaceutical industry experience to the board of this micro-cap company (Market Cap: ₹53 Cr).
- Mr. Ashok Kumar Ramawat has 46 years of post-qualification experience in the Pharmaceuticals Industry
- The director was originally appointed to the board on 25th August, 2020
- Continuation of directorship beyond age 75 is subject to a Special Resolution at the 41st AGM
- The Board meeting approving this continuation lasted 1 hour, from 04:30 P.M. to 05:30 P.M. on August 11, 2026
Biofil Chemicals reported a 92% YoY revenue increase to ₹12.35 cr for Q1 FY27, primarily driven by a surge in the Chemical division's trading activities. However, Net Profit plummeted 95.4% YoY to ₹0.11 cr, largely because the base quarter (Q1 FY26) was inflated by ₹2.83 cr in Other Income. The core Pharma division reported a segment loss of ₹0.06 cr as manufacturing facilities undergo a 3-6 month renovation to comply with revised Schedule M regulations. Operating margins remain extremely thin as the company relies on trading to sustain top-line growth during this transition.
- Revenue from operations increased 92% YoY to ₹12.35 cr, representing ~44% of TTM revenue in a single quarter.
- Net Profit fell sharply to ₹0.11 cr from ₹2.41 cr in the previous year's corresponding quarter.
- Chemical division revenue grew 481% YoY to ₹9.22 cr, though it contributed only ₹0.15 cr to segment results.
- Pharma division reported a segment loss of ₹6.41 lakhs compared to a profit of ₹2.70 cr in Q1 FY26.
- Manufacturing facility renovation and upgradation for Schedule M compliance is expected to take 3-6 months.
Biofil Chemicals & Pharmaceuticals has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the period ended June 30, 2026. The certificate, issued by Ankit Consultancy Private Limited, confirms that share certificates received for dematerialization were processed, mutilated, and cancelled within the required 15-day timeframe. This is a standard administrative filing required for all listed companies to ensure the integrity of electronic shareholding records. There are no financial or operational updates included in this disclosure.
- Compliance certificate submitted for the quarter ended June 30, 2026
- Securities received for dematerialization were mutilated and cancelled within 15 days
- Registrar and Share Transfer Agent (RTA) confirmed the substitution of depository names in the register of members
- Company maintains a low debt-to-equity ratio of 0.14 as per latest financial context
Biofil Chemicals & Pharmaceuticals Limited has announced the closure of its trading window starting July 1, 2026, in compliance with SEBI Insider Trading regulations. The closure is necessitated by the upcoming consideration of un-audited financial results for the quarter ending June 30, 2026. The restriction applies to all designated persons, their immediate relatives, and connected persons. The trading window will reopen 48 hours after the financial results are officially declared to the stock exchanges.
- Trading window closure effective from Wednesday, July 1, 2026.
- Closure is for the purpose of approving un-audited financial results for the quarter ended June 30, 2026.
- Trading window to reopen 48 hours after the results become generally available.
- Company has implemented PAN-level freezing for Designated Persons as per SEBI circulars.
- The specific date for the Board Meeting to approve results will be announced separately.
Biofil Chemicals reported a significant 399% increase in annual net profit to ₹278.60 lakhs for FY26, compared to ₹55.78 lakhs in FY25. This surge was primarily driven by a massive spike in 'Other Income' which reached ₹308.23 lakhs, while core revenue from operations actually declined by 15% YoY to ₹2839.52 lakhs. For the fourth quarter (Q4 FY26), the company recorded a net profit of ₹21.22 lakhs on revenue of ₹756.56 lakhs. Despite the revenue drop, the company managed to reduce its total annual expenses by 15% to ₹2802.79 lakhs.
- Annual net profit surged to ₹278.60 lakhs in FY26 from ₹55.78 lakhs in FY25.
- Other Income spiked to ₹308.23 lakhs in FY26, up from just ₹30.52 lakhs in the previous year.
- Revenue from operations for FY26 decreased by 15% to ₹2839.52 lakhs compared to ₹3340.22 lakhs in FY25.
- Total annual expenses were reduced to ₹2802.79 lakhs from ₹3297.13 lakhs YoY.
- Q4 FY26 revenue stood at ₹756.56 lakhs with a net profit of ₹21.22 lakhs.
The promoter group of Biofil Chemicals & Pharmaceuticals Limited, led by Chairman Ketan Shah, has submitted a disclosure under SEBI Takeover Regulations for the financial year ended March 31, 2026. The promoters collectively hold 76,14,760 equity shares in the company. Crucially, they have confirmed that no direct or indirect encumbrance or pledging of these shares occurred during the financial year. This routine disclosure provides transparency regarding the stability of the promoter's stake.
- Promoter group collectively holds 76,14,760 equity shares as of March 31, 2026
- Official confirmation that zero shares were pledged or encumbered during the financial year
- Compliance filing under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations
- Promoter group includes key management personnel such as Chairman and MD Ketan Shah
Biofil Chemicals & Pharmaceuticals Limited has issued a mandatory notice to shareholders holding physical shares to furnish PAN, KYC, bank details, and nominations. This action is in compliance with the SEBI Master Circular dated February 06, 2026, to ensure seamless communication and regulatory adherence. Shareholders who do not comply will be unable to lodge grievances or avail service requests from the Registrar and Share Transfer Agent (RTA). Additionally, all future payments such as dividends will be processed exclusively through electronic mode once the requirements are met.
- Mandatory submission of PAN, KYC, and Bank Account details for all physical share folios
- Compliance is driven by SEBI Master Circular dated February 06, 2026
- RTA will only process grievances and service requests after the furnishing of required KYC documents
- Future dividend and interest payments to be made strictly via electronic mode for compliant folios
- Shareholders can submit details via In-Person Verification (IPV), self-attested hard copies, or electronic mode with e-sign
Biofil Chemicals & Pharmaceuticals has announced a special window for the transfer and dematerialization of physical securities purchased before April 01, 2019, following a SEBI circular. This window is operational for exactly one year, from February 05, 2026, to February 04, 2027. Securities processed under this facility will be credited in demat mode and will be subject to a mandatory one-year lock-in period from the date of registration. This move is designed to resolve legacy documentation issues for long-term physical shareholders.
- Special window for physical share dematerialization open from Feb 05, 2026, to Feb 04, 2027
- Applies to securities sold or purchased prior to April 01, 2019, including previously rejected requests
- Mandatory one-year lock-in period for securities transferred through this special window
- Transferred securities will be credited exclusively in demat mode to the transferee
- Shareholders must coordinate with RTA Ankit Consultancy Private Limited for documentation
Biofil Chemicals & Pharmaceuticals Limited has filed the compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The document confirms that for the quarter ended March 31, 2026, all share dematerialization requests were handled according to regulatory timelines. The Registrar, Ankit Consultancy Pvt. Ltd., verified that physical certificates were cancelled and the depository's name was updated in the records within 15 days. This is a standard administrative filing ensuring the integrity of the company's shareholding records.
- Quarterly compliance for SEBI (Depositories and Participants) Regulations, 2018 completed.
- Dematerialization requests processed and confirmed within the mandatory 15-day window.
- Physical share certificates were mutilated and cancelled after due verification by the Registrar.
- Registrar Ankit Consultancy Private Limited issued the confirmation for the period ending March 31, 2026.
Financial Performance
Revenue Growth by Segment
Total turnover decreased by 16.82% to INR 3370.74 lacs in FY25 compared to INR 4052.50 lacs in FY24. The Pharma Unit revenue fell 4.33% to INR 2666.03 Lacs, while the Chemicals Unit revenue saw a significant decline of 44.59% to INR 674.18 Lacs.
Geographic Revenue Split
100% of operations are conducted within India; the company reported no separate geographical segments in its financial disclosures.
Profitability Margins
Operating profit margin improved from 2.25% to 2.61% YoY. Net profit margin also saw a slight increase from 1.82% to 1.91%, despite a 35.79% drop in absolute net profit to INR 57.87 lacs.
EBITDA Margin
Operating profit margin stood at 2.61% for FY25, up from 2.25% in FY24, indicating a slight improvement in core operational efficiency despite lower overall sales volumes.
Capital Expenditure
The company is currently divesting assets rather than expanding, having sold plant, machinery, and leasehold land at its Sanwer Road unit to Cyano Pharma and Formo Plast. It also proposed the disposal of 80,156 square meters of leasehold rights at Pithampur to consolidate operations.
Credit Rating & Borrowing
The company maintains a very low Debt-Equity ratio of 0.03 (up from 0.02) and a strong Interest Coverage Ratio of 24.14, indicating minimal reliance on external debt and high capacity to service interest from earnings.
Operational Drivers
Capacity Expansion
The company is pursuing a consolidation strategy rather than expansion, moving operations to a single location to optimize resources. It is disposing of its Sanwer Road assets and a vacant 80,156 sq meter portion of industrial land in Pithampur.
Raw Material Costs
Cost of Goods Sold increased in FY25 due to higher purchase of goods, which contributed to a 47.47% decrease in the inventory turnover ratio.
Manufacturing Efficiency
The company is focusing on enhancing efficiency through consolidation; however, inventory turnover dropped from 19.93 to 10.47 (-47.47%), indicating a temporary slowdown in moving stock.
Strategic Growth
Expected Growth Rate
15%
Growth Strategy
Growth is targeted through the consolidation of operations to reduce overheads, a focus on new product launches in the generics and branded markets, and increasing volume growth to capitalize on improved demand in the domestic pharma sector.
Products & Services
Pharmaceutical products (generics and branded) and Chemical products.
Brand Portfolio
Biofil
New Products/Services
The company is focusing on new product launches in the generics and branded segments to drive mid-teen growth in the 2025-2026 period.
Market Expansion
Focusing on domestic-focused growth with a pick-up in volume for generics and branded products.
Strategic Alliances
The company entered into agreements to sell assets to Cyano Pharma Private Limited and Formo Plast Private Limited as part of its operational restructuring.
External Factors
Industry Trends
The pharma sector is growing due to improved US generics performance and raw material cost moderation. Domestic companies are expected to see mid-teen growth (approx 15%) in FY26 driven by new launches and volume gains.
Competitive Landscape
The company operates in a competitive domestic pharma market where success depends on product launch speed and volume growth.
Competitive Moat
The company's moat is based on its multi-segment presence in both Pharma and Chemicals and its low-debt profile (0.03 D/E), which provides financial stability during market downturns.
Macro Economic Sensitivity
The company is sensitive to global and domestic economic factors, including the performance of the US generics market and fluctuations in raw material costs.
Consumer Behavior
Increased demand for branded products and generics is a key trend driving the company's current product strategy.
Geopolitical Risks
Global economic factors are cited as risks that could materially influence operations, particularly in the pharmaceutical export and generics markets.
Regulatory & Governance
Industry Regulations
Operations are governed by SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and Indian Accounting Standards (Ind-AS).
Legal Contingencies
The company faced a fine of INR 95,000 imposed by stock exchanges (BSE/NSE) for delays in regulatory submissions/disclosures.
Risk Analysis
Key Uncertainties
The 44.59% drop in Chemical segment revenue and the 37.40% decrease in debtors' turnover indicate significant risks in revenue stability and cash flow collection efficiency.
Geographic Concentration Risk
100% concentration in the Indian market, specifically with manufacturing roots in Madhya Pradesh.
Technology Obsolescence Risk
The company is addressing operational efficiency through consolidation but has not detailed specific digital or R&D technology shifts.
Credit & Counterparty Risk
The decrease in debtors' turnover to 0.94 suggests a potential risk in the quality of receivables or a significant extension of credit terms to customers.
